BMP Sunstone Reports First Quarter 2009 Financi...(luted share comparedto a non-GAAP net lo...),Health

Date:5/18/2009

luted share, compared to a non-GAAP net loss of $106,000, or ($0.00) per diluted share, in the first quarter of 2008. The EPS calculation is based on 40.8 million diluted shares, compared to 35.1 million diluted shares in the prior year period. On a GAAP basis, the Company reported net loss of $2.0 million in the first quarter of 2009, or ($0.05) per share, compared to a net loss of $2.8 million, or ($0.08) per share, in the prior year period.

First quarter financial results include non-cash items related to the Company's convertible notes. These include $4.6 million in deferred loan costs, debt discount and debt premium, relative to the early extinguishment of debt, offset by a $1.6 million gain on the embedded derivatives in the January 2009 notes and common stock warrants issued as part of the February 2009 equity issuance.

Balance Sheet

As of March 31, 2009, the Company had cash and cash equivalents of $21.2 million and notes receivable of $18.8 million, totaling $40.0 million. Notes receivables are notes accepted from customers for the settlement of trade receivable balances. All notes receivables are guaranteed by established banks in China and have maturities of six months or less.

Financial Guidance

BMP Sunstone is reiterating its revenue, non-GAAP and EBITDA guidance for 2009. As previously announced, for the fiscal year 2009, revenue is anticipated to increase at least 35% year over year to reach $150 to $160 million. EBITDA is expected to reach $16 million to $18 million, and non-GAAP net income is expected to reach $9 million to $11 million.

Gao continued, "China's healthcare opportunity is large and growing. We believe our combination of branded OTC products at Sunstone, in-licensed RX products at BMP China, and our established distribution networks -- which enable us to control sales channels in key markets -- position us very competitively.
'/>"/>

SOURCE BMP Sunstone Corporation Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
2. BMP Sunstone to Report First Quarter 2008 Financial Results
3. BMP Sunstone Announces Participation in May Investor Conferences
4. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
5. BMP Sunstone Reports First Quarter 2008 Financial Results
6. BMP Sunstone Announces Participation in June Investor Conferences
7. BMP Sunstone Announces Official Launch of Ferriprox in PRC
8. BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd
9. BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co.
10. BMP Sunstone to Report Third Quarter 2008 Financial Results
11. BMP Sunstone Announces Exchange Offer of $10.7 Million of Outstanding Secured Notes